Skip to main content
MindBio Therapeutics Corp. logo

MindBio Therapeutics Corp. — Investor Relations & Filings

Ticker · MBIO ISIN · CA60256C2076 CSE Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 113 across all filing types
Latest filing 2026-04-15 Regulatory Filings
Country CA Canada
Listing CSE MBIO

About MindBio Therapeutics Corp.

https://mindbiotherapeutics.com/

MindBio Therapeutics Corp. develops and commercializes AI-powered health prediction technologies utilizing proprietary acoustic biomarkers extracted from the human voice. The company's core offering is a comprehensive enterprise platform designed for real-time intoxication and impairment detection, primarily focusing on sobriety verification in safety-critical environments. This platform employs machine learning algorithms to analyze over 140 acoustic parameters, such as jitter, shimmer, and spectral entropy, achieving greater than 88% prediction accuracy in under three seconds. Target markets include zero-tolerance industries like aviation, mining, and construction, requiring scalable, non-invasive fitness-for-duty verification. The technology transforms speech into actionable health intelligence for workforce monitoring and advanced telehealth applications.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a short corporate press release announcing the appointment of a market maker (venture liquidity provider) for MindBio Therapeutics. It does not present financial statements, quarterly results, governance materials, or fundraising details; instead it is a general regulatory announcement that doesn’t fit any specialized category. As a catch‐all for miscellaneous regulatory disclosures, it falls under “Regulatory Filings (RNS).”
2026-04-15 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing a new technology deployment (“Intox Collect™”) and includes a correction regarding the completion and terms of a private placement. It does not constitute a formal financial report (no quarterly or annual financial statements), nor is it a transcript, AGM material, management change notice, or detailed investor presentation. It does touch on fundraising (private placement), but the primary purpose is a business/technology announcement with an embedded financing correction. There is no specific category for a general corporate press release, so this falls into the residual Regulatory Filings category.
2026-04-13 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing new product technology (Intox Collect™) and includes a correction to a prior news release regarding the closing of a private placement (finder’s fees and warrants issued). It is not an earnings release (no financial highlights or quarterly results), not an annual or interim report, not an M&A or governance update, and does not attach a formal report. It is a general regulatory/news announcement that does not fit into other specific categories. Therefore it falls into the fallback category for miscellaneous regulatory filings.
2026-04-13 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Canadian Form 51-102F3 Material Change Report detailing the closing of a non-brokered private placement, including proceeds raised, unit and warrant issuance, and use of proceeds. This is a direct update on the company’s fundraising and capital structure change. Therefore, it falls under Capital/Financing Update (CAP).
2026-04-10 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Canadian NI 51-102 Form 51-102F3 Material Change Report announcing the closing of an upsized non-brokered private placement, detailing the number of units issued, gross proceeds, use of proceeds, and related terms. This is a corporate financing/fundraising announcement rather than a full financial report or other governance filing. It directly pertains to the company’s capital raising activity, fitting the Capital/Financing Update category.
2026-04-10 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is a Canadian securities regulatory Form 45-106F1 – Report of Exempt Distribution filed on SEDAR+. It provides detailed mandatory disclosure under National Instrument 45-106 regarding an exempt distribution of securities, including issuer, underwriter, distribution details, purchaser schedules, compensation, and directors/officers information. This is not an earnings release, annual report, or management discussion; it is a regulatory compliance filing. It does not announce a report’s publication but is the report itself. Therefore, it falls under the fallback category for miscellaneous regulatory filings (RNS).
2026-04-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.